Webdisclosure.com

Search

VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

Directive transparence : information réglementée

20/04/2022 12:01

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

20.04.2022 / 12:01
The issuer is solely responsible for the content of this announcement.



Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

 

HALLE (SAALE) / MUNICH, GERMANY, April 20, 2022 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, will participate at the following conferences:


Kempen Life Sciences Conference
Date: April 21, 2022, 10:30 am CEST
Venue: Amsterdam, The Netherlands
Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics


HAIB Stockpicker Summit
Date: May 11-13, 2022
Venue: Berlin, Germany
Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics


H.C. Wainwright Global Investment Conference
Date: May 25, 2022, 3:30 pm EDT (9:30 pm CEST)
Venue: Miami, FL, USA
Participant: Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics

A webcast of the presentation will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company's website at www.vivoryon.com and will be archived on the Company's website for 30 days following the conference.


BIO International Convention
Date: June 13-16, 2022
Venue: San Diego, CA, USA
Participants: Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO of Vivoryon Therapeutics

###


About Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com

Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.


For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com

Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
 



20.04.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@vivoryon.com
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1331093

 
End of News DGAP News Service

1331093  20.04.2022 

fncls.ssp?fn=show_t_gif&application_id=1331093&application_name=news&site_id=symex